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23 :2 79AbstractCandidate gene studies have reported CYP19A1 variants to be associated with endometrial
cancerandwithestradiol (E2) concentrations.Weanalyzed2937singlenucleotidepolymorphisms
(SNPs) in 6608 endometrial cancer cases and 37 925 controls and report the first genome wide-
significant association between endometrial cancer and a CYP19A1 SNP (rs727479 in intron 2,
PZ4.8!10K11). SNP rs727479 was also among those most strongly associated with circulating
E2 concentrations in 2767 post-menopausal controls (PZ7.4!10
K8). The observed endometrial
cancer odds ratio per rs727479 A-allele (1.15, CIZ1.11–1.21) is compatible with that predicted by
the observed effect on E2 concentrations (1.09, CIZ1.03–1.21), consistent with the hypothesis that
endometrial cancer risk is driven by E2. From 28 candidate-causal SNPs, 12 co-located with three
putative gene-regulatory elements and their risk alleles associated with higher CYP19A1
expression in bioinformatical analyses. For both phenotypes, the associations with rs727479 were
stronger among women with a higher BMI (PinteractionZ0.034 and 0.066 respectively), suggesting
a biologically plausible gene-environment interaction.CY
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s study.Established risk factors for endometrial cancer include
high BMI (IARC 2002), early menarche, late menopause,
nulliparity, estrogen-only hormone replacement therapy
(HRT) (Beral et al. 2005) and tamoxifen use (Cuzick et al.
2003), while cigarette smoking and the use of oral
contraceptives or combined HRT (Beral et al. 2005) are
associated with lower risks. It has been hypothesized that
these factors alter endometrial cancer risk by increasing
exposure to estrogens (Key & Pike 1988); indeed, higher
concentrations of circulating estradiol (E2) in post-
menopausal women have been associated with an
increased risk of endometrial cancer (Zeleniuch-Jacquotte
et al. 2001, Lukanova et al. 2004, Allen et al. 2008).
After the cessation of ovarian estrogen production at
menopause, endogenous estrogens are primarily syn-
thesized from testosterone (T) in adipose tissue via
aromatase, encoded by CYP19A1. Candidate gene studies
have found levels of E2 in pre-menopausal and post-
menopausal women, and also in men, to be associated
with genetic variants within or close to CYP19A1
(Dunning et al. 2004, Paynter et al. 2005, Haiman et al.
2007, Ahn et al. 2009, Eriksson et al. 2009, Kidokoro et al.
2009, Travis et al. 2009, Beckmann et al. 2011, Lundin
et al. 2012, Prescott et al. 2012, Flote et al. 2014).
Candidate studies have also identified associations
between several different CYP19A1 variants and endo-
metrial cancer (Paynter et al. 2005, Tao et al. 2007,
Setiawan et al. 2009, Low et al. 2010), with some evidence
of stronger associations in women with higher BMI
(Setiawan et al. 2009).None of the published studies have attempted a
systematic assessment of all common CYP19A1 variants
in order to determine i) which are most likely to be causal
for endometrial cancer and/or E2 concentration, ii)
whether multiple independent causal variants exist at
this locus for either trait, and iii) whether the same variant
or variants are responsible for both traits. The latter would
help to address the question as to whether the reported
association between E2 and endometrial cancer seen in
epidemiological studies is causal or a consequence of
confounding (Fig. 1). If the association is causal, then
variants causally associated with E2 levels should also be
associated with endometrial cancer, with a magnitude
that can be predicted using a Mendelian randomization
methodology (C-Reactive Protein Coronary Heart Disease
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23 :2 80Genetics Collaboration et al. 2011, Interleukin-6 Receptor
Mendelian Randomisation Analysis Consortium 2012), a
form of instrumental variable analysis in which the
instrument is a genetic variant(s) known to be associated
with the biomarker in a particular direction.
To address the question of whether the same CYP19A1
variant(s) are associated with E2 levels and endometrial
cancer with compatible effect sizes and directions, we used
genotype information for 2937 single nucleotide poly-
morphisms (SNPs) across a 1.2 Mb region encompassing
CYP19A1 in 6608 endometrial cancer cases and 37 925
controls of European ancestry, 1733 of whom (all controls)
were post-menopausal and had measured E2 and T
concentrations.Materials and methods
Endometrial cancer case–control studies
The association between SNPs at the CYP19A1 locus and
endometrial cancer was tested using data from four
separate case-control studies:
The ANECS, SEARCH, and NSECG genomewide
association studies The results presented here are
based on the ANECS, SEARCH, and NSECG genomewide
association studies (GWAS) and country-matched datasets
(McGregor et al. 1999, WTCCC 2007, Houlston et al. 2010,
McEvoy et al. 2010, Painter et al. 2011, Spurdle et al. 2011),
as shown in Supplementary Table 1A and B, see section on
supplementary data given at the end of this article, and
described in detail in (Painter et al. 2015). All cases and
controls were of European ancestry.
The ECAC iCOGS study The fourth dataset comprised
4402 women of European ancestry with a confirmed diag-
nosis of endometrial cancer (3535 with confirmed
endometrioid histology), recruited via 11 separate studies
in seven countries in the Endometrial Cancer Association
Consortium (ECAC; Painter et al. 2015) and 28 758
healthy female controls from the same countries, all
participating in the Breast Cancer Association Consortium
(BCAC; Michailidou et al. 2013) or the Ovarian Cancer
Association Consortium (OCAC; Pharoah et al. 2013), plus
282 Norwegian blood donor controls (see Supplementary
Information, Supplementary Table 1A and B, see section
on supplementary data given at the end of this article).
Cases and controls were genotyped for 211 155 SNPs using
a custom Illumina Infinium iSelect array (‘iCOGS’;
Michailidou et al. 2013, Pharoah et al. 2013, Painter
et al. 2015) designed by the Collaborative Oncologicalhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0386
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Printed in Great BritainGene-environment Study (‘COGS’). The iCOGS array
includes 134 SNPs located within the w1.2 Mb region of
chromosome 15 between 50 899 000–52 095 000 sur-
rounding CYP19A1, 22 of which had been specifically
selected for the study of post-menopausal E2 levels.
Post-genotyping quality control for all four studies
was as described in (Spurdle et al. 2011) and (Painter et al.
2015). Individuals with !85% estimated European
ancestry based on Identity-By-State (IBS) scores between
study individuals and individuals in HapMap (http://
hapmap.ncbi.nlm.nih.gov/) were excluded.E2 datasets
The EPIC Norfolk study Sex-hormone levels, includ-
ing E2 and T concentrations, were measured on subsets of
the w25 000 participants in the European Prospective
Investigation of Cancer-Norfolk cohort study (see Day
et al. (1999) for details). After recruitment, participants
were invited to attend a first health check (HC1), at which
a blood sample was taken. A second blood sample was
taken from participants who attended the second health
check (HC2),w3 years after the first. For each set of blood
samples, a subset were randomly selected for hormone
level measurement from among the women who were
considered to be post-menopausal based on being O55
years, not having menstruated in the last year, and having
not taken HRT for at least 3 months before sampling
(Supplementary Table 1C, see section on supplementary
data given at the end of this article). The plasma and serum
samples collected from these women had been stored at
K70 8C until analysis, and their whole blood samples
had been stored atK30 8C before DNA extraction. 2368 of
the women for whom hormone levels had been measured
had also been genotyped using the iCOGS array as BCAC
control subjects (and thus were also controls in our iCOGS
endometrial cancer analysis). Of these, 1333 women had
hormones measured from their HC1 blood sample and
1536 from their HC2 sample, of whom 501 had hormones
measured from both samples. Where two measurements
existed, we chose the measurement from HC2, when
women would be further from the menopause. After
excluding women within 2 years of the menopause
at blood draw or with missing E2 levels or E2 values
O300 pmol/l (i.e., outside the possible range for a post-
menopausal woman) our analysis was based on 1500
genotyped women with HC2 E2 levels and 425 women
with HC1 levels. Of the HC2 women, 1431 also had a valid
T measurement (T was not measured as part of HC1).Published by Bioscientifica Ltd.
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23 :2 81Ethical approval was obtained from the Norwich Local
Research Ethics Committee, LREC 98CN01. All study
participants provided written informed consent.
The SIBS study Participants in the Sisters in Breast
Screening study (SIBS) were identified through the
National Health Service breast screening program in the
UK (Prescott et al. 2012). A subset of 905 SIBS women who
were aged over 55 years at recruitment, 2 or more years
since their last menstrual period, and not currently using
HRT at the time of blood collection were selected for
hormone measurement (Prescott et al. 2012). After
excluding women with missing or extreme E2 levels
(as above), 889 women were left, of whom 302 had been
genotyped using the iCOGS array as BCAC control
subjects (after quality control exclusions), and thus were
also controls in our iCOGS endometrial cancer analysis
(Supplementary Table 1C, see section on supplementary
data given at the end of this article). All participants gave
informed written consent. This study was approved by the
Eastern Multicentre Research Ethics Committee (SIBS).
For the EPIC and SIBS studies, plasma E2 concen-
trations were measured at The Royal Marsden Hospital
(London, UK), using an in-house RIA using a highly
specific rabbit antiserum which had been raised against
an E2-6-carboxymethyloxime- BSA conjugate and E2-6-
carboxymethyloxime-[2K125I] iodohistamine (Dowsett
et al. 1987). The detection limit was 3 pmol/l and values
were replaced with this limit when they were reported as
being undetectable. For the SIBS study, at a concentration
of 25 pmol/l the within assay variation was 6.5% and the
between assay variation was 16% (nZ18). For the EPIC
studies, at a concentration of 18 pmol/l the within assay
and the between-batch coefficients of variation (CV) were
8.6 and 13% respectively.
Testosterone was measured in the EPIC and SIBS
studies using a solid-phase RIA kit (Diagnostic Products,
Gwynedd, UK), with within- and between-batch CV at a
concentration of 3.1 nmol/l of 6.1 and 10% respectively
and with a detection limit of 0.14 nmol/l.
Additional SIBS replication set To increase statisti-
cal power we genotyped all of the 889 SIBS women with
E2 measurements (described above) for rs727479 using a
Custom Taqman Assay (Life Technologies, ThermoFisher
Scientific,Waltham,MA, USA) according tomanufacturer’s
instructions (details provided in Supplementary Table 5, see
section on supplementary data given at the end of this
article). After quality control exclusions described below,
813 women hadmeasured E2 measurements and genotypeshttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0386
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Printed in Great Britainfor rs727479,ofwhom264alsohadvalid iCOGSgenotyping
i.e., 549 additional samples.Regional imputation
We used IMPUTEv2 (Howie et al. 2009) to impute
genotypes for SNPs in the 50 899 000–52 095 000 region
of chromosome 15 in the 1000 Genomes dataset v3 (April
2012 release). We allowed the IMPUTE Software to select
the most appropriate haplotypes from among the
complete set of 1000 Genomes haplotypes (Howie et al.
2011). Imputation was conducted separately for the
four datasets, and SNPs with imputation information
score !0.7 and/or MAF !0.01 in any of the four studies
were excluded.Statistical analysis
The four imputed endometrial cancer datasets were
analyzed separately using unconditional logistic
regression with a per-allele (1 degree of freedom) model
using SNPTEST v2 (Ferreira & Marchini 2011). For the
iCOGS dataset, analyses were performed adjusting for
country and for the first ten principal components, as in
(Painter et al. 2015). The GWAS datasets were each
analyzed as a single stratum, with adjustment for the
first two (ANECS and NSECG) and three (SEARCH)
principal components. Our ongoing genome-wide
analyses have shown that the inclusion of these principal
components is sufficient to control for population
stratification (genomic control lZ1.002–1.038).
The endometrial cancer odds ratios (OR) for the four
studies were combined using standard fixed-effects meta-
analyses. The I2 statistic (Higgins & Thompson 2002) was
used to estimate the proportion of the variance due to
between-study heterogeneity. SNPs with significant
between-study heterogeneity (P!0.05) were excluded.
Analyses for all SNPs were repeated adjusting for the most
significant SNP to assess whether multiple independent
causal variantswere present. A statistical significance cut-off
ofP%10K4wasused for secondaryandconditional analyses.
To determine the most likely candidate causative SNPs,
the log likelihoods of all tested SNPs were compared with
that of the top SNP. SNPs with log-likelihood ratios of
!1:100ofbeing the topSNPandwhichwere correlatedwith
the top SNP (linkage disequilibrium (LD) r2O0.2) were
prioritized as potentially causal variants for follow-up in
bioinformatic and functional analyses (Udler et al. 2010).
The analyses were repeated restricting the iCOGS
and NSECG studies to those cases with endometrioidPublished by Bioscientifica Ltd.
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23 :2 82or non-endometrioid histology (the ANECS and
SEARCH GWAS sample sets contained only endometrioid
histology cases).
Associations between SNPs and E2 concentrations
were tested using the natural logarithm transformed
ratio of E2 to T concentrations, adjusting for laboratory
batch, study (EPIC HC2 or SIBS), age and BMI at blood
draw, prior HRT use (yes or no) and menopausal status
(2–5 years since menopause orO5 years since menopause)
using ProbABEL software (Aulchenko et al. 2010). Given
the family-based design of the SIBS study, we used the
matrix of kinship coefficients to adjust for the non-
independence of relatives. This approach is also expected
to avoid the effects of population stratification (Chen &
Abecasis 2007).
For the analysis including the additional genotyping
in the SIBS samples, the data were re-analyzed for all 2767
women, using the sandwich variance estimator to obtain
standard errors robust to familial clustering (in the absence
of a kinship coefficient matrix for the complete set).
The associations between the most significant SNP
and the two phenotypes (endometrial cancer and E2
concentration) were repeated after stratifying the datasets
according to quartiles of age diagnosis (cases) or interview
(controls) or quartiles of BMI. These analyses were
restricted to the iCOGS dataset (plus the SIBS replication
set for the E2 analysis), as BMI was not available for all
cases and controls in the GWAS sets. Since T concentration
had not been measured in the EPIC HC1 women, the
analyses stratified by BMI and age were based on log-
transformed E2 concentrations uncorrected for T, in order
to maximise the sample size and hence the statistical
power. Quartiles were based on the variables’ distributions
in cases, to ensure roughly equivalent statistical power
across the quartiles. The same categories were used for the
E2 analysis to allow direct comparisons between the two
phenotypes.
We used a Mendelian randomization style approach
to compare the observed association of the top SNP with
endometrial cancer with that predicted based on a SNP’s
effect on E2 levels. For this we re-estimated the effect of
each effect allele on E2 (b) adjusting only for study and
laboratory batch. Using a published estimate of the
endometrial cancer OR associated with a doubling of
post-menopausal E2 concentration (Lukanova et al. 2004),
wemultiplied the natural logarithm of this OR by the ratio
(lnb/ln2) to obtain a predicted endometrial cancer OR per
effect allele. We then compared this predicted OR to that
observed, to assess whether the observed association
between the SNP and endometrial cancer is compatiblehttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0386
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Printed in Great Britainwith a causal association between higher post-menopausal
E2 concentration and endometrial cancer. In the same
way, we compared the predicted effect of the top SNP on
breast cancer risk (based on a published estimate of the
effect of doubling E2 concentration on breast cancer risk
(Key et al. 2002)) with that observed in the iCOGS BCAC
study of 45 290 breast cancer cases and 41 880 controls of
European ancestry (Michailidou et al. 2013).
All statistical analyses used R software unless other-
wise stated, and all statistical tests were two-sided. The
association plot was produced using LocusZoom (Pruim
et al. 2010).Results
The CYP19A1 association with endometrial cancer is
explained by a single signal
Genetic imputation of the w1.2 Mb region of chromo-
some 15 between 50 899 000–52 095 000 using the April
2012 release of the 1000 Genomes reference panel in four
independent case–control sets yielded post-QC genotype
information for 2937 SNPs in 6608 endometrial cancer
cases and 37 925 controls (Supplementary Table 1A, see
section on supplementary data given at the end of this
article). Of these SNPs, 100 had been genotyped in the
largest study (iCOGS), and 191, 201, and 187 in the three
GWAS sets (SEARCH, ANECS, and NSECG GWASs
respectively).
Combining results across the four studies, 171 SNPs
had P!1!10K4, compared with an expected number of
less than one under the null hypothesis (Supplementary
Table 2, see section on supplementary data given at the
end of this article). Fifty SNPs were significant at the
conventional GWAS threshold of 5!10K8, of which
rs727479 in intron 2 was the most significantly associated
(OR per A alleleZ1.15, CIZ1.11–1.21, PZ4.81!10K11,
Table 1, Fig. 2A). This SNP was directly genotyped in all
four studies, and the strength of the association did not
differ among studies (I2Z0.0%, PhetZ0.92). (Supple-
mentary Table 2, see section on supplementary data
given at the end of this article, Supplementary Fig. 1A).
Conditioning on rs727479, no other SNPs reached
P!10K4 (Supplementary Table 2).
These results suggest that rs727479, or a SNP
correlated with it, is causally related to disease. Based on
a likelihood ratio threshold of 1:100 (Udler et al. 2010), 28
SNPs remain as possible causal variants (Supplementary
Table 2, see section on supplementary data given at
the end of this article); all are correlated with rs727479Published by Bioscientifica Ltd.
Table 1 SNP rs727479 A-allele associations with endometrial cancer and with circulating E2 levels
Ncases/Nctrls fcase/fctrl OR (95% CI) P value Pinteraction
Endometrial cancer 6608/37 925 0.688/0.651 1.15 (1.11, 1.21) 4.81!10K11
BMI Q1 (!24.3 kg/m2) 715/5463 0.668/0.643 1.08 (0.95, 1.24) 0.25
BMI Q2 (24.3–28.0 kg/m2) 718/4372 0.677/0.648 1.12 (0.98, 1.29) 0.10
BMI Q3 (28.0–33.2 kg/m2) 702/2910 0.697/0.648 1.21 (1.04, 1.40) 0.012
BMI Q4 (R33.2 kg/m2) 721/1254 0.709/0.651 1.25 (1.05, 1.49) 0.012 0.047
Age Q1 (!57.0 years) 1005/14 106 0.679/0.653 1.10 (1.00, 1.22) 0.060
Age Q2 (57.0–63.0years) 1079/5309 0.679/0.652 1.10 (0.98, 1.23) 0.10
Age Q3 (63.0–69.0 years) 1145/4699 0.693/0.644 1.28 (1.15, 1.44) 1.73!10K5
Age Q4 (R69.0 years) 1081/2948 0.701/0.651 1.24 (1.08, 1.42) 0.0019 0.19
Histology:
Endometrioid 5611/37 925 0.690/0.651 1.16 (1.11, 1.22) 1.12!10K10
Non-endometrioid 887/37 925 0.678/0.651 1.08 (0.98, 1.20) 0.13 0.15
Nsamples f b (se) P value
E2 levels 2767 0.656 0.096 (0.018) 7.40!10
K8
BMI Q1 (!24.3 kg/m2) 868 0.656 0.052 (0.032) 0.11
BMI Q2 (24.3–28.0 kg/m2) 985 0.650 0.097 (0.031) 0.0020
BMI Q3 (28.0–33.2 kg/m2) 664 0.671 0.122 (0.036) 8.45!10K4
BMI Q4 (R33.2 kg/m2) 250 0.642 0.096 (0.058) 0.099 0.066
Age Q1 (!57.0 years) 287 0.656 0.095 (0.083) 0.25
Age Q2 (57.0–63.0 years) 802 0.661 0.104 (0.030) 5.65!10K4
Age Q3 (63.0–69.0 years) 789 0.653 0.080 (0.032) 0.013
Age Q4 (R69.0 years) 889 0.654 0.105 (0.031) 6.48!10K4 0.90
F, frequency of the rs727479 A allele; age is in years; Q1–Q4 are quartiles of the distribution of BMI or age in the endometrial cases. The endometrial cancer
analysis by quartiles is adjusted for age. E2 concentrations are log transformed and adjusted for laboratory batch, study, age at blood draw, BMI, HRTuse and
menopausal status.
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rs727479, rs17601876, rs12050767, and rs749292).
Considering only the 5611 endometrioid–histology
cases, 41 SNPs had P!5!10K8, of which rs727479 was the
most significant (OR per A alleleZ1.16, CIZ1.11–1.22,
PZ1.12!10K10, Table 1). The effect estimate was
somewhat smaller in the analysis restricted to the 887
non-endometrioid cases (ORZ1.08, CIZ0.98–1.20,
PZ0.13), although the difference in allele frequencies
between endometrioid and non-endometrioid cases
was not significant (PZ0.15, Table 1). No SNPs reached
P!1!10K4 in the analysis restricted to the non-endome-
trioid histology cases (nZ887) (Supplementary Table 2, see
sectionon supplementarydata given at the endof this article).Stronger associations between rs727479 and endometrial
cancer in women of older age and higher BMI
There was some suggestion of a stronger association
between rs727479 and endometrial cancer among older
women (ORZ1.28 (1.15–1.44) PZ1.7!10K5 and ORZ1.24
(1.08–1.42) PZ1.9!10K3 for the third and fourth quartiles
of age respectively; Table 1), although the interaction
between rs727479 and age was not significant (PZ0.19).
BMI was available for 2858 cases and 14 098 controls
from the iCOGS studies. As expected, BMI was positivelyhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0386
q 2016 The authors
Printed in Great Britainassociated with endometrial cancer risk (ORZ1.60
(1.54–1.66) per quartile, P!10K100). SNP rs727479 was
not associated with BMI in previous analyses (PZ0.94 in
theO230 000 GIANT consortium participants (Locke et al.
2015))_ENREF_24 nor in the iCOGS controls (PZ0.31).
There was evidence of a stronger disease association for
rs727479 among women with higher BMI (interaction
PZ0.034, which was slightly attenuated when adjusted for
age, PZ0.047), with the strongest association among
women in the highest quartile (ORZ1.25 (1.05–1.49),
PZ0.012, adjusting for age), (Table 1, Fig. 3A).The set of correlated SNPs most significantly associated
with endometrial cancer are all within the set of SNPs
most significantly associated with the E2:T ratio
T is the substrate for aromatization to E2, and the ratio
of E2 to T concentrations, in essence, corrects for the
variation in T levels. This correction would be expected
to lead to a more direct relationship with aromatase
activity, hence we used the E2:T ratio as the hormonal
phenotype in our initial fine-mapping of the CYP19A1
region. Circulating E2 and T concentrations were
measured in 1733 healthy post-menopausal women
from the EPIC Norfolk (NZ1431) and SIBS (NZ302)
studies (Dunning et al. 2004, Prescott et al. 2012) whoPublished by Bioscientifica Ltd.
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Figure 2
Association of SNPs in the CYP19A1 region with (A) endometrial cancer and
(B) E2:T, highlighting rs727479. Each point indicates the statistical significance
of the association between a SNP and endometrial cancer (Fig. 2A) or
between a SNP and the E2:T ratio (Fig. 2B). Squares denote SNPs directly
genotyped by the iCOGS array; circles are SNPs for which genotypes were
imputed. The larger purple square is rs727479, the SNP with the strongest
evidence of association with endometrial cancer. Other colours show the
strength of linkage disequilibrium between each SNP with rs7277479.
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Imputation and post-imputation QC identical to that
performed in the endometrial cancer analysis resulted in
1956 SNPs across the CYP19A1 region, of which 100 had
been genotyped.
Adjusting for age, BMI, HRT use and menopausal
status, 105 SNPs were associated with the E2:T ratio at
P!1!10K4, including the lead endometrial cancer SNP
rs727479 (PZ2.06!10K7). Two imputed SNPs had very
slightly smaller P values than rs727479 (rs12592697,
PZ1.46!10K7 and rs4775935, PZ1.89!10K7), both of
which were in near-complete LD with rs727479 (r2Z0.99).
Ninety four SNPs had odds of at least 1:100 compared with
rs12592697 of being the causal E2:T SNP, and also have
r2O0.2 with rs12592697 (Supplementary Table 2, see
section on supplementary data given at the end of this
article). Conditioning on rs12592697, no SNPs have
P!1!10K4; hence there is no evidence of a second signal
for E2:T in this region. The set of 95 SNPs contains all 28
non-excluded endometrial cancer candidate SNPs. Since
rs727479 was the most significant of the genotyped SNPs
and was statistically almost indistinguishable from the top
two SNPs, rs727479 was used as the representative SNP for
the set of 95 non-excluded SNPs. The rs727479 A allele was
associated with higher E2 concentration (bZ0.092,http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0386
q 2016 The authors
Printed in Great BritainPZ3.80!10K5) and, to a lesser extent, with lower
T concentration (bZK0.045, PZ0.057).
Including an additional 485 women from the EPIC-
Norfolk cohort for whom E2 but not T concentrations had
been measured (and therefore the E2:T ratio could not be
computed), the association between rs727479 and E2
became stronger (bZ0.094, PZ3.1!10K6). To further
increase the statistical power we genotyped rs727479 in
the remaining 549 SIBS samples for whom E2 concen-
trations had beenmeasured. In the full set of 2767 women,
the association between E2 concentrations and rs727479
approached the genome-wide significance threshold
(bZ0.096, PZ7.4!10K8) (Table 1).
There was no evidence of a difference in the
association between rs727479 and E2 concentration with
age (PinteractionZ0.90, Table 1). The rs727479-E2 associ-
ation was the strongest among women with the highest
BMIs, with borderline significant evidence of an
interaction (PinteractionZ0.066, Table 1, Fig. 3B).Evidence that higher E2 concentration is causal for
endometrial cancer
Following a Mendelian randomization argument, if
elevated E2 concentration were causally associated withPublished by Bioscientifica Ltd.
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Figure 3
Association of SNP rs727479 with (A) endometrial cancer and (B) E2 levels,
by quartile of BMI distribution. In Fig. 3A the log(OR) of endometrial cancer
associated with each A allele of SNP rs727479 is shown for each quartile of
the BMI distribution, adjusting for age. There is a borderline significant
interaction between genotype and BMI quartile (PZ0.047). Figure 3B
shows the regression coefficient (b) for the association between each
A allele of rs727479 and log-transformed E2 levels (adjusted for laboratory
batch, study, age at blood draw, BMI, HRT use and menopausal status),
(PinteractionZ0.066). For both plots, the error bars are 95% CI, and the
quartiles are based on the BMI distribution in endometrial cancer cases,
to allow for comparability between plots, and to ensure sufficient cases in
each quartile.
CYP19A1
re727478-A
10% increase (6–14%)
per A-allele
Endometrial
cancer
Circulating postmenopausal
estradiol levels
Observed per-A allele
OR: 1.15 (1.11–1.21)
Predicted per-A allele
OR: 1.09 (1.03–1.21)
OR=2.06 (1.47–2.89) for
doubling of levels (ref. 6)
Figure 4
The observed and predicted risks of endometrial cancer associated with
each rs727479 A allele. The Observed per-A allele OR is that observed in this
study of 6608 and 37 925 endometrial cancer cases and controls.
The predicted per-A allele OR is estimated based on the observed association
between rs727479 and E2 levels in 2767 healthy post-menopausal women,
and on the endometrial cancer OR associated with a doubling of
post-menopausal E2 levels reported by Lukanova et al. (2004).
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23 :2 85endometrial cancer (as opposed to an association
produced by confounding), then we would expect any
SNP which raises E2 to be proportionally associated with
endometrial cancer. We observed an rs727429 per-A-allele
increase in adjusted E2 concentration of 10% (95%
CIZ6–14%, from the regression coefficient in Table 1 for
log-transformed levels). Lukanova et al. (2004) estimated
that the odds ratio for endometrial cancer associated with
a doubling of post-menopausal E2 concentration was
2.06 (CIZ1.47–2.89; it was necessary to use an external
estimate because hormone levels had only been
measured in control subjects in our study). Based on this
published estimate, the predicted per-allele OR forhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0386
q 2016 The authors
Printed in Great Britainendometrial cancer would be 1.09 (CIZ1.03–1.21),
which is consistent with that observed in our study
(ORZ1.15, CIZ1.11–1.21) (Fig. 4).Candidate causal variants may regulate CYP19 expression
Bioinformatic analysis defined three putative regulatory
elements (PREs) coincident with 12 of 28 candidate
endometrial cancer causal variants prioritized by genetic
analysis (Fig. 5). Altered binding of transcription factors
was predicted for 10/12 candidates located within PREs,
including top candidate rs727479 (Supplementary Table 3,
see section on supplementary data given at the end of
this article). For four of these (rs8024515, rs7181429,
rs28637352, and rs28490942) there was experimental
evidence for differential transcription factor (TF) binding
in the cell types tested by ENCODE (Fig. 5) and SNPs
rs7181429, rs28637352 overlap binding consensus
sequences for NFIC and ZBTB7A in Ishikawa endometrial
cancer cells (Fig. 5). Expression analysis identified nominal
associations (P!0.05) between risk alleles for the 28
candidate causal variants and greater CYP19A1 expression
in several tissues, with candidate SNP rs7181429’s associ-
ation with expression in blood passing a Bonferroni-
corrected significance threshold (PZ6.0!10K5; corrected
PZ1.62!10K4; Supplementary Table 4, see section on
supplementary data given at the end of this article).Discussion
We conducted the largest comprehensive genetic study to
date of SNPs across the CYP19A1 hormone metabolismPublished by Bioscientifica Ltd.
Candidate risk variants
H3K4Me1 ENCODE
H3K27Ac ENCODE
Chromatin state Stem cells
Adipocyte cells
DNasel HS Ishikawa
Ishikawa ChIP-seq NFIC
ZBTB7A
ENCODETF ChIP-seq
ENCODE
CYP19A1
rs12595627
rs4775935
rs727479
rs8029537
rs28490942
rs28637352
rs7181429
rs749292
rs12050767
rs7175531
rs7173595
rs8024515
PRE-1
PRE-2
PRE-3
Figure 5
Candidate endometrial risk variants coincide with three PREs. The 28 best
candidate causal SNPs map towards the 3 0 end of the CYP19A1 gene. The
functional elements displayed were accessed through the UCSC Genome
Browser and include: H3K4Me1 and H3K27Ac histone modifications
measured by the Encyclopedia of DNA Elements (ENCODE) project in seven
cell lines; open chromatin as delineated by DNaseI hypersensitivity sites (HS)
in Ishikawa endometrial cancer cells (previously incorrectly named ECC-1))
and 125 other cell types; TF binding in Ishikawa cells and 91 cell lines within
ENCODE: 21/28 candidates are predicted to overlap TF binding sites.
Roadmap Epigenomics Project chromatin state segmentation of adipose-
derived mesenchymal stem cells and adipocytes: orange bars represent
enhancers and red bars represent regions flanking active transcription start
sites. Twelve SNPs, marked by dbSNP rsIDs, are located in PREs: highlighted
in blue. PREs were defined by the presence of histone modifications, DHS,
TF binding and Roadmap enhancers.
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risk and circulating E2 concentration. Using genotype
information on nearly 3000 SNPs we have, for the first
time, identified GWAS-level significant associations
between SNPs in this region and endometrial cancer.
Our finding that rs727479 is the most significantly
associated SNP in this region confirms the findings of a
previous candidate-SNP study (Setiawan et al. 2009) and
provides a list of 28 SNPs which cannot be excluded as
causal on the basis of statistical analyses. We found no
evidence for further causal variants outside of this set. For
example, rs749292, previously reported as a possible
second signal (Setiawan et al. 2009), was not significantly
associated with risk in our analysis after conditioning onhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0386
q 2016 The authors
Printed in Great Britainrs727479, given the number of SNPs included in the
analysis (PcondZ0.017).
This is the first study to look at the CYP19A1
endometrial cancer association by histology. The most
significant risk SNP, rs727479, appears to be more strongly
associated with endometrioid histology endometrial
tumors than with the rarer and poorer prognosis non-
endometrioid cancers. However, the confidence intervals
for the two ORs are not incompatible, and there was no
significant difference in allele frequencies between the
women with endometrioid and non-endometrioid tumors
(PZ0.15). Despite the common description of non-
endometrioid tumours as ‘estrogen independent’, recent
work has shown that the two subtypes largely sharePublished by Bioscientifica Ltd.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research D J Thompson et al. CYP19A1 SNPs, estradiol and
endometrial cancer
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endogenous or exogenous estrogen exposure (Setiawan
et al. 2013), consistent with our findings.
We also confirmed at a borderline GWAS significance
level (PZ7.4!10K8) the association between rs727479
and E2 concentration previously reported in post-meno-
pausal women (Haiman et al. 2007, Ahn et al. 2009,
Beckmann et al. 2011, Prescott et al. 2012) and in males
(Travis et al. 2009). It had been reported that rs749292 and
rs727479 may act independently to alter levels (Haiman
et al. 2007), but we found no association between rs749292
and E2 concentration after conditioning on rs727479
(PZ0.20). Our sample set partially overlaps with that
included in the GWAS of hormone levels reported by
Prescott et al. (2012), (the additional 549 SIBS women
genotyped here for rs727479 had all been included in the
Prescott et al. GWAS), but a combination of nearly 2000
extra subjects, denser genotyping in and around the
CYP19A1 gene and imputation to the 1000 Genomes
reference panel allowed us to look in more detail at the
region. Our results suggest the existence of a single causal
variant in CYP19A1 underlying both E2 concentration
and endometrial cancer, although we cannot exclude
the possibility that there are instead multiple causal
variants which are in sufficiently strong linkage disequili-
brium that they are indistinguishable by epidemiological
analysis.
We estimate that rs727479 accounts for 1.1% of the
variance in post-menopausal E2 concentration (in con-
trast, BMI accounts for 16% of the variance). Given that
the estimated heritability of post-menopausal E2 is around
40% (Varghese et al. 2012) it is clear that further genetic
variants that affect E2 concentration remain to be found.
The predominant source of circulating estrogens in
post-menopausal women is adrenal androgens (T), which
are converted to estrogens in peripheral adipose tissues,
with the final stage of this process requiring aromatase,
the enzyme encoded by the CYP19A1 gene. Although E2
concentrations and endometrial cancer risks are both
higher in women with larger BMI regardless of CYP19A1
genotype, there also appears to be a gene-environment
interaction such that the associations of the rs727479
A allele with E2 concentration and also with endometrial
cancer risk increase according to BMI, with BMI pre-
sumably serving as a proxy for the amount of adipose
tissue (Fig. 1). Whole body aromatization is known to be
directly associated with BMI and the aromatization rate
per cell has been found to increase with increasing age
(Cleland et al. 1985). Together these data suggest that thehttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0386
q 2016 The authors
Printed in Great Britaininfluence of the SNP may be more profound when the
aromatization rate is already higher.
Twelve of the 28 candidate causal variants (including
top candidate rs727429) lie in PREs. Further, the risk alleles
of candidates located in PRE-3 associate with increased
CYP19A1 expression, and ENCODE and other data
(Eeckhoute et al. 2006, Lee & Maeda 2012) indicate that
the NFIC and ZBTB7A TFs may affect PRE-3 repressor
activity in endometrial cancer cells. Taken together these
lines of evidence indicate that candidate causal variants
within PRE3 should have high priority for follow-up
studies to test their effects on CYP19A1 promoter activity
through long-range chromatin interactions.
Using a Mendelian randomization argument with
CYP19A1 genotype as the instrumental variable, we have
shown that the endometrial cancer OR per A-allele of
rs727479 predicted on the basis of the per-allele effect on
E2 (1.09, CIZ1.03–1.21) is in line with the directly
observed effect of each A allele on endometrial cancer
(ORZ1.15, CIZ1.11–1.21) (Fig. 4). Whereas previous
epidemiological studies have observed a positive corre-
lation between E2 concentration and risk, it has not been
possible to distinguish between a causal relationship and
one produced by confounding. By exploiting the random
allocation of alleles to individuals at conception, Mende-
lian randomization mimics a randomized control trial,
thus removing possible confounding. We have therefore
found good evidence that higher post-menopausal E2
concentrations are indeed a causal risk factor for endo-
metrial cancer, in line with other evidence such as the
observed increase in risk associated with estrogen-only
HRT but not with estrogenCprogesterone HRT (Beral et al.
2005). Hence lowering E2 levels has the potential to be a
useful strategy for reducing risk. Ideally we would like
to be able to test this hypothesis in a prospective study,
whereby E2 levels are measured at baseline for a cohort of
healthy post-menopausal women who are then followed
up for endometrial cancer incidence. However, such a
study would need to be extremely large in order to accrue
sufficient cancer cases within a reasonable time frame.
It would also be interesting to repeat the study in a
non-European setting in order to see whether the results
are consistent across populations.
In Mendelian randomization, for a genetic variant to
be a suitable instrument, in addition to being associated
with the biomarker it must also be i) independent of
the unobserved confounders of the biomarker-disease
relationship and ii) associated with the disease only via
the biomarker. Population stratification is the most
obvious way in which condition i) can be violated.Published by Bioscientifica Ltd.
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European ancestry and adjusted for principal components.
Condition ii) can be broken by pleiotropy, or similarly if
the variant is in LD with a separate disease-associated
variant. It is impossible to be certain that this condition
has been met, and our finding that the observed
association between rs727479 and endometrial cancer is
slightly stronger than that predicted according to
rs727479’s effect on E2 levels may in part be due to the
SNP additionally acting on endometrial cancer risk via
a pathway not involving circulating E2. A Mendelian
randomization using an instrument consisting of multiple
independent E2-associated SNPs, as and when they are
reported (e.g., via larger GWAS) is one way to minimize
the potential impact of pleiotropy on the results. We are
confident that the results are not due to reverse causation,
since E2 measurements were all carried out in women from
the control arm of the endometrial cancer study.
Despite higher endogenous E2 concentration also
being a known risk factor for breast cancer (Key et al.
2002), candidate SNP studies of CYP19A1 have not
reported an association with breast cancer (Haiman et al.
2007). Based on the 45 290 European-ancestry breast
cancer cases and 41 880 controls from the BCAC iCOGS
study, none of the 171 CYP19A1 locus SNPs with P!10K4
for endometrial cancer were associated with breast cancer
(Michailidou et al. 2013) (minimum PZ0.0033, data not
shown). This may in part be because E2 concentration is
less strongly related to breast than to endometrial cancer;
a doubling of E2 concentration has been reported to be
associated with an OR of 1.29 (CIZ1.15–1.44) for breast
cancer (Key et al. 2002), from which we would predict a
breast cancer OR of 1.03 (1.01–1.07) per A allele of
rs727479. This predicted effect size is consistent with
that observed for breast cancer in BCAC (ORZ1.02
(1.00–1.04); PZ0.10), but the effect size is too small to be
confidently detected, even in a breast cancer study of
this size.
In conclusion, we have confirmed at a genome-wide-
level of significance the association between endometrial
cancer and variants within the CYP19A1 gene, and shown
that all of the reported associations can be explained by
a single risk peak. We have also provided evidence that
the same set of variants is associated with higher E2
concentration in post-menopausal women, supporting a
causal role for E2 in endometrial cancer. For both traits, the
SNP associations were stronger in women with a higher
BMI, suggesting a biologically plausible gene-environment
interaction.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0386
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